Literature DB >> 24648559

Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany.

Martin Kaase1, Florian Szabados2, Agnes Anders3, Sören G Gatermann3.   

Abstract

Due to the increase in multidrug-resistant Enterobacteriaceae, the interest in older antimicrobial agents, like fosfomycin, has increased. In this study, we used agar dilution for testing susceptibilities to fosfomycin in a collection of 107 carbapenem-nonsusceptible Enterobacteriaceae isolates, of which 80 produced various types of carbapenemases, including KPC, VIM, NDM, and OXA-48. Overall, 78% of the strains had fosfomycin MICs of ≤ 32 mg/liter and were thus considered to be susceptible according to the current EUCAST breakpoint. The MIC50 and MIC90 were 8 mg/liter and 512 mg/liter, respectively. Escherichia coli strains had significantly lower fosfomycin MICs than the Klebsiella pneumoniae and Enterobacter cloacae strains. Furthermore, comparisons of the susceptibility testing methods, like Etest and disk diffusion, were performed against agar dilution as the reference method. Essential agreement between Etest and agar dilution was 78.9%, and categorical agreement between the two methods was 92.5%, with 20% very major errors and 2.6% major errors. Disk diffusion was studied with 50-μg and 200-μg fosfomycin disks, but no inhibition zone breakpoint that reduced very major and major errors to an acceptable level was found. Etest and disk diffusion showed poor agreement with fosfomycin agar dilution.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24648559      PMCID: PMC4042753          DOI: 10.1128/JCM.03484-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

Review 1.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.

Authors:  Maria Souli; Irene Galani; Stefanos Boukovalas; Michael George Gourgoulis; Zoi Chryssouli; Kyriaki Kanellakopoulou; Theofano Panagea; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

3.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 4.  The revival of fosfomycin.

Authors:  Argyris S Michalopoulos; Ioannis G Livaditis; Vassilios Gougoutas
Journal:  Int J Infect Dis       Date:  2011-09-25       Impact factor: 3.623

5.  Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae.

Authors:  Fernando Pasteran; Celeste Lucero; Melina Rapoport; Leonor Guerriero; Irene Barreiro; Ezequiel Albornoz; Omar Veliz; Alejandra Corso
Journal:  J Infect Dev Ctries       Date:  2012-05-14       Impact factor: 0.968

Review 6.  Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.

Authors:  Drosos E Karageorgopoulos; Rui Wang; Xu-Hong Yu; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2011-11-16       Impact factor: 5.790

7.  Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort.

Authors:  Bryan T Alexander; Jonas Marschall; Robert J Tibbetts; Elizabeth A Neuner; W Michael Dunne; David J Ritchie
Journal:  Clin Ther       Date:  2012-06       Impact factor: 3.393

Review 8.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

9.  Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.

Authors:  Elizabeth A Neuner; Jennifer Sekeres; Gerri S Hall; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

10.  Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates.

Authors:  Pak-Leung Ho; Jane Chan; Wai-U Lo; Eileen L Lai; Yuk-Yam Cheung; Terrence C K Lau; Kin-Hung Chow
Journal:  J Med Microbiol       Date:  2013-08-29       Impact factor: 2.472

View more
  28 in total

Review 1.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

2.  First Detection of a Fosfomycin Resistance Gene, fosA7, in Salmonella enterica Serovar Heidelberg Isolated from Broiler Chickens.

Authors:  Muhammad A Rehman; Xianhua Yin; Marissa G Persaud-Lachhman; Moussa S Diarra
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

3.  Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.

Authors:  I Portillo-Calderón; M Ortiz-Padilla; B de Gregorio-Iaria; V Merino-Bohorquez; J Blázquez; J Rodríguez-Baño; J M Rodríguez-Martínez; A Pascual; F Docobo-Pérez
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

4.  Frequency and Mechanisms of Spontaneous Fosfomycin Nonsusceptibility Observed upon Disk Diffusion Testing of Escherichia coli.

Authors:  Aaron E Lucas; Ryota Ito; Mustapha M Mustapha; Christi L McElheny; Roberta T Mettus; Sarah L Bowler; Serena F Kantz; Marissa P Pacey; A William Pasculle; Vaughn S Cooper; Yohei Doi
Journal:  J Clin Microbiol       Date:  2017-12-26       Impact factor: 5.948

5.  Successful treatment of a disseminated infection with extensively drug-resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin-based multidrug regimen.

Authors:  J P Mills; M B Wilck; B C Weikert; P M Porrett; D Timko; K Alby; R A Bonomo; E A Blumberg
Journal:  Transpl Infect Dis       Date:  2016-09-07       Impact factor: 2.228

Review 6.  Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?

Authors:  Federico Perez; Nadim G El Chakhtoura; Krisztina M Papp-Wallace; Brigid M Wilson; Robert A Bonomo
Journal:  Expert Opin Pharmacother       Date:  2016-03-09       Impact factor: 3.889

7.  Carbapenem- and Colistin-Resistant Enterobacter cloacae from Delta, Colorado, in 2015.

Authors:  Andrew P Norgan; Jarred M Freese; Patricia M Tuin; Scott A Cunningham; Patricio R Jeraldo; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

8.  Complete Sequence of a Novel IncR-F33:A-:B- Plasmid, pKP1034, Harboring fosA3, blaKPC-2, blaCTX-M-65, blaSHV-12, and rmtB from an Epidemic Klebsiella pneumoniae Sequence Type 11 Strain in China.

Authors:  Dai-Rong Xiang; Jun-Jie Li; Zi-Ke Sheng; Hai-Ying Yu; Mei Deng; Sheng Bi; Fei-Shu Hu; Wei Chen; Xiao-Wei Xue; Zhi-Bo Zhou; Yohei Doi; Ji-Fang Sheng; Lan-Juan Li
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

9.  Diversity of Carbapenemase-Producing Escherichia coli Isolates in France in 2012-2013.

Authors:  Lauraine Gauthier; Laurent Dortet; Garance Cotellon; Elodie Creton; Gaëlle Cuzon; Valérie Ponties; Rémy A Bonnin; Thierry Naas
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

10.  Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome.

Authors:  Iain J Abbott; Elke van Gorp; Rixt A Wijma; Joseph Meletiadis; Jason A Roberts; Johan W Mouton; Anton Y Peleg
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.